Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Patent
1984-05-17
1987-06-30
Naff, David M.
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
435 19, 436 56, 436 57, 436900, A61K 4900, C12Q 144, G01N 5348, G01N 3700
Patent
active
046769749
ABSTRACT:
Pancreatic exocrine function is determined by a breath test method wherein a radioactive labelled ester such as cholesterol octanoate is ingested in the body and is hydrolyzed by pancreatic enzymes and oxidized to labelled Co.sub.2 which is expired in the breath. The rate of appearance of labelled Co.sub.2 in the breadth is a function of the rate of hydrolysis by pancreatic enzymes which in turn reflects pancreatic exocrine function. Before ingestion, the ester is mixed with a carrier substrate such as a triglyceride to form a lipid matrix containing the ester and the lipid matrix is suspended in aqueous solution. To insure that low levels of expired labelled Co.sub.2 is due to pancreatic exocrine insufficiency, the ester is ingested simultaneously with a differentially labelled unesterfied carboxylic acid or the test method is repeated with an added step of simultaneously ingesting the ester with exogenously provided pancreatic enzymes.
REFERENCES:
patent: 3844894 (1974-10-01), Kronick et al.
patent: 3917812 (1975-11-01), Woog et al.
Blomstrand et al., "Acta Chir. Scand.", 134:667-669 (1968).
Cole Stephen G.
Hofmann Alan F.
Naff David M.
The Regents of the University of California
LandOfFree
Breath test for pancreatic exocrine function does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Breath test for pancreatic exocrine function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Breath test for pancreatic exocrine function will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-446904